Predictive Value of the Low-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio for the Prevention of Stroke Recurrence in Japanese Patients Treated with Rosuvastatin

被引：0
作者：
Michiya Igase
Katsuhiko Kohara
Ryosuke Katagi
Shiro Yamashita
Mutsuo Fujisawa
Tetsuro Miki
机构：
[1] Ehime University Graduate School of Medicine,Department of Geriatric Medicine
[2] Ryotenkai Katagi Neurosurgery,Proteo Medicine Research Center
[3] Ehime University Graduate School of Medicine,undefined
来源：
Clinical Drug Investigation | 2012年 / 32卷
关键词：
Chronic Kidney Disease; Ischaemic Stroke; Acute Ischaemic Stroke; Rosuvastatin; Haemorrhagic Stroke;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: HMG-CoA-reductase (statin) therapy to reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with coronary heart disease can substantially improve outcomes; however, the benefits of statins in stroke patients, particularly for secondary stroke prevention, remain poorly under stood. Moreover, the degree of decrease in LDL-C that is required to prevent the recurrence of stroke is unknown.
引用
收藏
页码：513 / 521
页数：8
相关论文
共 52 条
[1]  
Rosenson R.S.(2004)Statins: can the new generation make an impression? Expert Opin Emerg Drugs 9 269-79
[2]  
La Rosa J.C.(2005)Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425-35
[3]  
Grundy S.M.(2003)Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 1149-58
[4]  
Walters D.D.(2004)Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 363 757-67
[5]  
Sever P.S.(1997)Reductase inhibitor monotherapy and stroke prevention Arch Intern Med 157 1305-10
[6]  
Dahlöf Poulter N.R.(2003)Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or = 12 months) follow-up intravascular ultrasound Circulation 108 2757-62
[7]  
Collins R.(2009)CKD Clinical Practice Guidebook The essence of treatment for CKD patients. Clin Exp Nephrol 13 191-248
[8]  
Armitage J.(1972)Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 499-502
[9]  
Parish S.(2009)Usefulness of aggressive lipid management for prevention of recurrence subsequent to PCI [in Japanese] Pharma Medica 27 93-9
[10]  
Crouse J.R.(2005)Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 1267-78
123456